Cellular Umbilical cord blood (UCB) derived allograft
By Phillip Steele, MD RMSK CAQ Sports Medicine
Performance Injury Care & Sports Medicine
Recent advancements in Stem Cell therapy has shown that mesenchymal stem cells (MCSC) have tremendous potential to help decrease the pain of osteoarthritis and improve joint function. There is considerable debate under way on what is considered the best source of stem cells. Although the majority of research has been devoted to adipose derived stem cells (ADSC) and bone marrow concentrate (BMC) recent advances in the processing of umbilical cord from BioBurst Rejuv has shown good results in terms of stem cells that activate into new tissue. Although many so called “Stem Cell Clinics” provide injections of stem cells from umbilical cord, few have the research to back up their claims of activation of these cells.
BioBurst Rejuv has considerable research showing that not only does their processing provide stem cells for injection, they have shown high degrees of activation and proliferation. They have also shown that in the BioBurst processing technique they have isolated growth factors and cytokines that stimulate stem cell activation.
Although no head to head study is available for comparing ADSC, BMC and UCB we are very encouraged by the research from BioBurst. We feel that by adding Bioburst to platelet rich plasma and releasate we can have a very robust response of cellular differentiation of MCSC to help you regenerate your osteoarthritic joint. For those interested in avoiding and minimizing the risk of bone marrow aspiration and or a shorter post procedural recovery period the addition of UCB will substantially shorten the activation of MCSC and provide an enhanced regenerative response.